Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0BH7Z
|
||||
| Former ID |
DNCL002791
|
||||
| Drug Name |
Girentuximab I-124
|
||||
| Synonyms |
Redectane (TN)
|
||||
| Drug Type |
Monoclonal antibody
|
||||
| Indication | Renal cancer [ICD9: 140-229, 189; ICD10:C64] | Phase 2 | [1] | ||
| Company |
Wilex
|
||||
| Target and Pathway | |||||
| Target(s) | Carbonic anhydrase IX | Target Info | Enhancer | [2], [3] | |
| KEGG Pathway | Nitrogen metabolism | ||||
| Pathway Interaction Database | HIF-1-alpha transcription factor network | ||||
| Reactome | Regulation of gene expression by Hypoxia-inducible Factor | ||||
| Reversible hydration of carbon dioxide | |||||
| WikiPathways | Vitamin D Receptor Pathway | ||||
| Reversible Hydration of Carbon Dioxide | |||||
| Regulation of Hypoxia-inducible Factor (HIF) by Oxygen | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00717587) Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer. U.S. National Institutes of Health. | ||||
| REF 2 | Potential role of (124)I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer. Biologics. 2012;6:395-407. | ||||
| REF 3 | Optical Imaging of Renal Cell Carcinoma with Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab. J Nucl Med. 2014 Jun;55(6):1035-40. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.